22nd Century Group (XXII) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
1 Feb, 2026Executive summary
Net revenues for Q2 2024 were $7.95M, up 22.8% sequentially but down 1.3% year-over-year, with gross profit turning positive at $0.6M from a prior loss.
Operating expenses dropped 76% to $2.62M, and net loss from continuing operations improved to $2.2M from $13.7M year-over-year.
The company shifted focus from cost containment to growth, rebuilding the executive team and emphasizing both branded and contract manufacturing.
Substantial doubt remains about the ability to continue as a going concern due to recurring losses and low cash.
Emphasis on relaunching and rebranding the VLN low-nicotine cigarette product to drive future growth.
Financial highlights
Q2 2024 net revenues were $7.95M, gross profit $0.6M (7.2% margin), and operating loss $2.0M, all showing significant improvement year-over-year.
Operating expenses fell to $2.6M in Q2 2024 from $11.1M in Q2 2023, reflecting cost reduction initiatives.
Cash used in operations for six months was $6.97M, a significant reduction from $37.33M in 2023.
Net total debt reduced to $7.0M as of June 30, 2024, from $13.3M at year-end 2023.
Cash and cash equivalents at June 30, 2024, were $1.28M; working capital deficit improved to ($2.25M).
Outlook and guidance
Targeting net income and cash-positive operations by Q1 2025, with revenue growth expected from new contract manufacturing volumes in H2 2024.
Management is evaluating further cost reductions and financing strategies, including asset sales and new securities issuance.
No assurance of raising sufficient capital; may need to liquidate assets or seek bankruptcy protection if unsuccessful.
Latest events from 22nd Century Group
- Special Meeting to vote on reverse split, new warrants, and equity offerings for Nasdaq compliance.XXII
Proxy filing23 Jun 2026 - Special Meeting seeks approval for reverse split, new warrants, and equity offerings to maintain Nasdaq listing.XXII
Proxy filing12 Jun 2026 - Registering 3M+ shares for resale, with dilution and going concern risks amid FDA-authorized focus.XXII
Registration filing12 Jun 2026 - Q1 2026 revenue was $4.1M, up sequentially but down year-over-year, with ongoing liquidity concerns.XXII
Q1 20267 May 2026 - Proxy seeks director election, executive pay approval, auditor ratification, and highlights growth strategy.XXII
Proxy filing29 Apr 2026 - Shelf registration enables up to $250M in offerings; $1.84M at-the-market sale supports VLN growth.XXII
Registration filing31 Mar 2026 - Net loss narrowed, debt eliminated, and VLN® distribution expanded for growth.XXII
Q4 202526 Mar 2026 - Low-nicotine cigarettes gain retail traction, targeting break-even and growth with no direct rivals.XXII
17th Annual LD Micro Main Event Conference17 Jan 2026 - Q3 2024 revenue dropped 24.5% with ongoing losses, but net debt and cost structure improved.XXII
Q3 202414 Jan 2026